| 178.88 2.19 (1.24%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 209.88 |
1-year : | 245.15 |
| Resists | First : | 179.69 |
Second : | 209.88 |
| Pivot price | 168.62 |
|||
| Supports | First : | 159.11 |
Second : | 146.38 |
| MAs | MA(5) : | 174.56 |
MA(20) : | 166.88 |
| MA(100) : | 160.33 |
MA(250) : | 131.57 |
|
| MACD | MACD : | 2.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 96.3 |
D(3) : | 92.4 |
| RSI | RSI(14): 62.7 |
|||
| 52-week | High : | 191.61 | Low : | 73.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GKOS ] has closed below upper band by 2.9%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 179.9 - 180.62 | 180.62 - 181.23 |
| Low: | 171.13 - 172 | 172 - 172.75 |
| Close: | 177.35 - 178.8 | 178.8 - 180.04 |
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Sat, 24 Oct 2026
What Glaukos Doubters Missed - Yahoo Finance
Sat, 24 Oct 2026
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo! Finance Canada
Fri, 23 Oct 2026
Glaukos Corporation Estimates – NYSE:GKOS - TradingView
Thu, 22 Oct 2026
Glaukos (NYSE:GKOS) - Stock Analysis - Simply Wall Street
Thu, 22 Oct 2026
Glaukos Corporation (GKOS) Options Chain - Yahoo! Finance Canada
Thu, 22 Oct 2026
Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 105.3 (%) |
| Shares Short | 3,850 (K) |
| Shares Short P.Month | 3,820 (K) |
| EPS | -3.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.6 |
| Profit Margin | -30.7 % |
| Operating Margin | -8.5 % |
| Return on Assets (ttm) | -5.2 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | 49.5 % |
| Gross Profit (p.s.) | 8.22 |
| Sales Per Share | 10.39 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 15 (M) |
| PE Ratio | -54.88 |
| PEG Ratio | 0 |
| Price to Book value | 15.42 |
| Price to Sales | 17.21 |
| Price to Cash Flow | -11105.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|